DBV Technologies announced that the Board of Directors has appointed existing board member, Michel de Rosen, as Non-Executive Chairman of the Board. Mr. de Rosen succeeds DBV Technologies’ co-founder, Dr. Pierre-Henri Benhamou, who retired from his position as DBV’s Non-Executive Chairman and board member. Dr. Benhamou will join the Company’s Scientific Advisory Board, effective immediately. Additionally, Daniel Tassé, Chief Executive Officer of DBV Technologies, has been appointed to the Board, replacing Dr. Pierre-Henri Benhamou. With these changes, effective immediately, DBV’s Board consists of eight directors. Mr. de Rosen has served on DBV’s Board of Directors since June 2018. He is currently Chairman of the Board of Faurecia, a global supplier of automotive equipment, and Chairman of the Board of Pharnext, a publicly-traded pharmaceutical company. Previously, he served as Chairman and Chief Executive Officer of Eutelsat, Chairman and Chief Executive Officer of ViroPharma and Chairman and Chief Executive Officer of Rhône-Poulenc Santé. Earlier in his career, Michel de Rosen held key positions at the French Ministries of Finance, Defense, Industry, and Telecommunications.